For a parent whose child has an inflammatory skin disease, pigmentation changes, rather than inflammation, might be the reason that he or she brought the child to the clinician.
There were no significant safety signals in the younger pediatric population, and no treatment-emergent adverse events suggestive of systemic JAK inhibition, Dr Lawrence Eichenfield said.